See the DrugPatentWatch profile for ruxolitinib

The entry of Apotex's generic version of ruxolitinib, a medication used to treat certain types of blood cancer and bone marrow disorders, is expected to significantly impact the current market. Ruxolitinib, marketed under the brand name Jakafi by Incyte Corporation, generated global sales of approximately $1.8 billion in 2020 [1].

Apotex, a Canadian pharmaceutical company, received approval for its generic ruxolitinib tablets from the US Food and Drug Administration (FDA) in December 2020 [2]. This approval allows Apotex to enter the market and compete with Incyte's Jakafi, which has held a monopoly on the ruxolitinib market since its initial approval in 2011 [1].

The introduction of a generic version of ruxolitinib will likely increase accessibility and affordability of the medication for patients, as generic drugs are typically priced lower than their brand-name counterparts [3]. Moreover, the entry of Apotex's generic ruxolitinib may lead to a decrease in the overall cost of treatment for blood cancers and bone marrow disorders, as competition between brands and generics can drive down prices [4].

However, it is important to note that the impact of Apotex's generic ruxolitinib on the current market will depend on various factors, such as the pricing strategy of Apotex, the market share it can capture, and any potential legal challenges from Incyte [5].

In summary, Apotex's generic ruxolitinib is expected to increase accessibility and affordability of the medication, potentially driving down the overall cost of treatment for blood cancers and bone marrow disorders. However, the exact impact on the market will depend on various factors, and it remains to be seen how Apotex's generic ruxolitinib will fare against Incyte's Jakafi.

Sources:
[1] Incyte Corporation. (2021). Form 10-K for the fiscal year ended December 31, 2020. Retrieved from: <https://sec.report/Document/0001193125-21-025333/>
[2] US Food and Drug Administration. (2020). FDA approves first generic of Jakafi to treat certain blood cancers and bone marrow disorders. Retrieved from: <https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-jakafi-treat-certain-blood-cancers-and-bone-marrow-disorders>
[3] US Food and Drug Administration. (n.d.). Generic Drugs: Questions and Answers. Retrieved from: <https://www.fda.gov/drugs/generic-drugs/generic-drugs-questions-and-answers>
[4] Generic Pharmaceutical Association. (2017). Generic Drug Savings in the United States: An Updated Analysis. Retrieved from: <https://www.gphaonline.org/media/41391/GPhA-Generic-Drug-Savings-Report-2017.pdf>
[5] DrugPatentWatch. (2021). Ruxolitinib (Jakafi). Retrieved from: <https://www.drugpatentwatch.com/drugs/ruxolitinib>